Literature DB >> 20951944

Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling.

Chozhavendan Rathinam1, Christine B F Thien, Richard A Flavell, Wallace Y Langdon.   

Abstract

Although myeloid leukemias are primarily caused by leukemic stem cells, the molecular basis of their transformation remains largely unknown. Here, by analyzing mice with a mutation in the RING finger domain of c-Cbl, we show that the E3 ubiquitin ligase activity of c-Cbl is required to restrict myeloid leukemia development. These mice develop a myeloproliferative disease which progresses to leukemia and involves hematopoietic progenitors that exhibit augmented FLT3 signaling. Suppressing this signaling through matings with FLT3 ligand knockout mice prevents leukemia development. We also observe enhanced c-Kit, Akt and Erk activity, and deregulated expression of leukemia-associated transcription factors in hematopoietic progenitors. The characterization of these perturbations provides direction for therapeutics that may aid the treatment of patients with c-Cbl mutations.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951944     DOI: 10.1016/j.ccr.2010.09.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  47 in total

Review 1.  Pathogenesis and consequences of uniparental disomy in cancer.

Authors:  Hideki Makishima; Jaroslaw P Maciejewski
Journal:  Clin Cancer Res       Date:  2011-04-25       Impact factor: 12.531

2.  Structural Determinants of the Gain-of-Function Phenotype of Human Leukemia-associated Mutant CBL Oncogene.

Authors:  Scott A Nadeau; Wei An; Bhopal C Mohapatra; Insha Mushtaq; Timothy A Bielecki; Haitao Luan; Neha Zutshi; Gulzar Ahmad; Matthew D Storck; Masashi Sanada; Seishi Ogawa; Vimla Band; Hamid Band
Journal:  J Biol Chem       Date:  2017-01-12       Impact factor: 5.157

3.  Oncogenic Signaling by Leukemia-Associated Mutant Cbl Proteins.

Authors:  Scott Nadeau; Wei An; Nick Palermo; Dan Feng; Gulzar Ahmad; Lin Dong; Gloria E O Borgstahl; Amarnath Natarajan; Mayumi Naramura; Vimla Band; Hamid Band
Journal:  Biochem Anal Biochem       Date:  2012-07-30

4.  CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.

Authors:  Paula Aranaz; Cristina Hurtado; Ignacio Erquiaga; Itziar Miguéliz; Cristina Ormazábal; Ion Cristobal; Marina García-Delgado; Francisco Javier Novo; José Luis Vizmanos
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

5.  Modeling CBL activating mutations in vivo.

Authors:  Stanley Chun-Wei Lee; Omar Abdel-Wahab
Journal:  Blood       Date:  2017-04-13       Impact factor: 22.113

Review 6.  RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.

Authors:  Stanley Lipkowitz; Allan M Weissman
Journal:  Nat Rev Cancer       Date:  2011-08-24       Impact factor: 60.716

7.  Nedd4-1 binds and ubiquitylates activated FGFR1 to control its endocytosis and function.

Authors:  Avinash Persaud; Philipp Alberts; Madeline Hayes; Sebastian Guettler; Ian Clarke; Frank Sicheri; Peter Dirks; Brian Ciruna; Daniela Rotin
Journal:  EMBO J       Date:  2011-07-15       Impact factor: 11.598

8.  c-Cbl and Cbl-b ligases mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with internal tandem duplication through the ubiquitin proteasome pathway.

Authors:  Gaku Oshikawa; Toshikage Nagao; Nan Wu; Tetsuya Kurosu; Osamu Miura
Journal:  J Biol Chem       Date:  2011-07-18       Impact factor: 5.157

Review 9.  Myeloproliferative neoplasm animal models.

Authors:  Ann Mullally; Steven W Lane; Kristina Brumme; Benjamin L Ebert
Journal:  Hematol Oncol Clin North Am       Date:  2012-08-21       Impact factor: 3.722

10.  Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.

Authors:  A Staffas; L S Arabanian; S Y Wei; A Jansson; S Ståhlman; P Johansson; L Fogelstrand; J Cammenga; F Kuchenbauer; L Palmqvist
Journal:  Oncogene       Date:  2016-09-12       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.